Literature DB >> 21692775

Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis.

M C G Winge1, K D Bilcha, A Liedén, D Shibeshi, A Sandilands, C-F Wahlgren, W H I McLean, M Nordenskjöld, M Bradley.   

Abstract

BACKGROUND: Filaggrin is a key protein involved in maintaining skin barrier function and hydration. Mutations in the filaggrin gene (FLG) cause ichthyosis vulgaris (IV) and are a major predisposing factor for atopic dermatitis (AD) in individuals of European and Asian descent. It has been proposed that FLG mutations are population specific and a difference in the spectra of mutations between different ancestral groups has been described. However, it is unknown whether FLG mutations in the African population are a causative genetic factor for IV and predispose to AD, or whether other mechanisms are more prominent.
OBJECTIVES: The present aim was to investigate the role of FLG mutations as predisposing factors for IV or AD among individuals from Ethiopia.
METHODS: A case series of Ethiopian patients with AD (n = 103) and IV (n = 7) together with controls (n = 103; subjects without past or present history of AD, dry skin or atopic manifestations) was collected at the outpatient dermatology clinics at ALERT Dermatology Hospital, Tikur Anbessa Hospital and Gondar University Hospital, Ethiopia. AD was diagnosed by a dermatologist using the U.K. Working Party's diagnostic criteria. The IV diagnosis was based on clinical examination and genetic testing of the steroid sulphatase gene to exclude X-linked recessive ichthyosis. Patients were studied with direct sequencing (n = 40) and/or allelic discrimination (n = 110). Immunohistochemical analysis was performed for filaggrin expression in the skin of patients (n = 7) and controls (n = 2).
RESULTS: The Ethiopian patients and controls were genotyped for the four previously described common European FLG null mutations (R501X, 2282del4, S3247X, R2447X) and no carriers were found. In one patient with AD a novel heterozygous 2-bp deletion, 632del2, leading to a premature stop codon was revealed by direct sequencing. No additional carrier of this deletion or other mutations was found. In addition, no difference in filaggrin expression was detected in AD or IV skin compared with healthy control skin.
CONCLUSIONS: Our results indicate that FLG loss-of-function-variants are less common in patients with IV and AD in the Ethiopian population, suggesting that other factors may be of importance in the pathogenesis in this ethnic group.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692775     DOI: 10.1111/j.1365-2133.2011.10475.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  34 in total

1.  Loss-of-function mutations in filaggrin gene associate with psoriasis vulgaris in Chinese population.

Authors:  Zhengmao Hu; Zhimin Xiong; Xiaojuan Xu; Fangfang Li; Lina Lu; Wei Li; Juan Su; Yalan Liu; Deyuan Liu; Zhiguo Xie; Yu Peng; Yehong Kuang; Lisha Wu; Jianglin Zhang; Qian Pan; Beisha Tang; Xiang Chen; Kun Xia
Journal:  Hum Genet       Date:  2012-03-11       Impact factor: 4.132

2.  Sebaceous gland, hair shaft, and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency.

Authors:  Robert Gruber; Jeffrey L Sugarman; Debra Crumrine; Melanie Hupe; Theodora M Mauro; Elizabeth A Mauldin; Jacob P Thyssen; Johanna M Brandner; Hans-Christian Hennies; Matthias Schmuth; Peter M Elias
Journal:  Am J Pathol       Date:  2015-02-07       Impact factor: 4.307

3.  Whole-exome sequencing indicates FLG2 variant associated with leg ulcers in Brazilian sickle cell anemia patients.

Authors:  Gabriela Queila de Carvalho-Siqueira; Galina Ananina; Bruno Batista de Souza; Murilo Guimarães Borges; Mirta Tomie Ito; Sueli Matilde da Silva-Costa; Igor de Farias Domingos; Diego Arruda Falcão; Iscia Lopes-Cendes; Marcos André Cavalcanti Bezerra; Aderson da Silva Araújo; Antônio Roberto Lucena-Araújo; Marilda de Souza Gonçalves; Sara Teresinha Olalla Saad; Fernando Ferreira Costa; Mônica Barbosa de Melo
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-12

Review 4.  Tight junctions in skin inflammation.

Authors:  Katja Bäsler; Johanna M Brandner
Journal:  Pflugers Arch       Date:  2016-11-16       Impact factor: 3.657

5.  Uncommon Filaggrin Variants Are Associated with Persistent Atopic Dermatitis in African Americans.

Authors:  David J Margolis; Nandita Mitra; Heather Gochnauer; Bradley Wubbenhorst; Kurt D'Andrea; Adam Kraya; Ole Hoffstad; Jayanta Gupta; Brian Kim; Albert Yan; Zelma Chiesa Fuxench; Katherine L Nathanson
Journal:  J Invest Dermatol       Date:  2018-02-08       Impact factor: 8.551

6.  Racial/Ethnic Differences in Incidence and Persistence of Childhood Atopic Dermatitis.

Authors:  Yuhree Kim; Maria Blomberg; Sheryl L Rifas-Shiman; Carlos A Camargo; Diane R Gold; Jacob P Thyssen; Augusto A Litonjua; Emily Oken; Maryam M Asgari
Journal:  J Invest Dermatol       Date:  2018-11-08       Impact factor: 8.551

Review 7.  Recent evolution of the human skin barrier.

Authors:  Erin A Brettmann; Cristina de Guzman Strong
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

8.  Filaggrin sequencing and bioinformatics tools.

Authors:  David J Margolis; Nandita Mitra; Bradley Wubbenhorst; Katherine L Nathanson
Journal:  Arch Dermatol Res       Date:  2019-08-01       Impact factor: 3.017

9.  Association of HLA-DRB1 genetic variants with the persistence of atopic dermatitis.

Authors:  David J Margolis; Nandita Mitra; Brian Kim; Jayanta Gupta; Ole J Hoffstad; Maryte Papadopoulos; Bradley Wubbenhorst; Katherine L Nathanson; Jamie L Duke; Dimitri S Monos; Malek Kamoun
Journal:  Hum Immunol       Date:  2015-08-22       Impact factor: 2.850

Review 10.  Molecular Genetic of Atopic dermatitis: An Update.

Authors:  Hani A Al-Shobaili; Ahmed A Ahmed; Naief Alnomair; Zeiad Abdulaziz Alobead; Zafar Rasheed
Journal:  Int J Health Sci (Qassim)       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.